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Coronavirus Disease 2019 (COVID‐19), caused by the Severe Acute Respiratory 
Syndrome Coronavirus-2 (SARS-CoV-2),  has infected more than 3.0 million people 
worldwide and killed more than 200,000 as of April 27, 2020, making it the most lethal 
pandemic since the Spanish flu of 1918.1, 2 COVID-19 may preferentially infect individuals 
with cardiovascular conditions,  is more severe in subjects with cardiovascular comorbidities, 
may directly or indirectly affect the heart and may interact with cardiovascular medications.3 
In addition, the widespread effects of the pandemic on the global healthcare system affects 
the routine and emergency cardiac care for patients who are, may be, or are not infected with 
COVID-19. In this White Paper authored by the Physicians and Scientists on the Editorial 
Board of the Journal of the American Heart Association (JAHA), we address the 
cardiovascular comorbidities of COVID-19 infection; the diagnosis and treatment of standard 
cardiovascular conditions during the pandemic; and the diagnosis and treatment of the 
cardiovascular consequences of COVID-19 infection. In addition, we will touch on the safety 
of healthcare workers and on ethical issues related to patient care in the COVID-19 era. 
 
COVID-19 disease and Troponin  
Take Home Points: 
• Elevated troponin levels are frequently seen in patients with COVID-19 disease; and 
are associated with increased severity of disease and risk of death. 
• In the absence of a specific etiology, elevated levels of troponins are likely due to 
myocardial injury from inflammation or a direct effect of SARS-CoV-2 infection. 
Research questions: 
• The role of troponin in clinical risk stratification, and as a prognostic factor of disease 
severity and mortality, needs to be further explored, particularly after accounting for other 
confounders. 
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• Mechanistic studies are needed to evaluate the cause of myocardial injury, and 
whether there is a potential for therapeutic options. 
 
Between 7 and 27.8% of COVID-19 patients may have elevated troponin levels4–7. In this 
section, we discuss the implications of elevated troponins, both in terms of etiology and 
clinical interpretation. 
Foremost, even during the on-going COVID-19 pandemic, the basic clinical tenets do 
not change: common causes of elevated troponin, such as type 1 myocardial infarction (MI)8, 
should be clinically excluded in all patients. If clinical suspicion for spontaneous MI arises, 
the modified pathways for ST-elevation myocardial infarction and acute coronary syndrome 
in the COVID-19 pandemic era can provide guidance to clinicians.9 It is also vital to 
understand that in the setting of SARS-Cov-2 infection, there is a greater possibility of type 2 
MI, due to a mismatch between myocardial oxygen demand and supply. Aside from these 
causes, COVID-19 patients should be clinically evaluated to exclude other common causes of 
troponin elevation, such as decompensated heart failure, arrhythmia, renal failure, hypoxemia 
and hypotension etc.  
SARS-CoV-2 infection is associated with systemic inflammation, and that may, in 
theory, contribute to the excess risk of type 1 myocardial infarction by destabilization of 
coronary atheromatous plaques, increased platelet aggregation and higher risk of stent 
thrombosis. However, to date there are no reports of an increase in STEMI risk associated 
with COVID-19 disease, although increased risk of myocardial infarction has been 
demonstrated in similar respiratory viral infections, such as influenza.10  
Other reasons for elevated troponin levels, more specific to SARS-COV-2 infection 
are: first, the virus appears to evoke a cytokine storm, resulting in intense activation of 
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inflammatory proteins.6 An association of high troponin levels has been seen with the 
elevated inflammatory markers in several cohorts,6, 7 suggesting direct myocardial 
inflammatory damage due to myocarditis.4 This could also reflect a hypercoagulable state 
causing microvascular thrombi and secondary MI.11 Second, it is also possible that the 
elevated troponin levels are due to coronary microvascular ischemia mediated by SARS-
CoV-2 binding of the endothelial ACE-2 receptor. Third, it could be due to direct myocarditis 
through cardiac viral infection. A specific section is dedicated to this issue in this article.   
Elevated troponin levels also have a strong prognostic implication in those with 
COVID-19 disease. Several studies have shown that those with elevated troponin levels at 
baseline have a greater risk of having a severe disease,11 increased intensive care unit 
admissions and significantly higher mortality.6, 7 In a cohort study,7 presence of elevated 
troponin levels were second to the presence of ARDS in the strength of association with 
mortality: hazard ratios were 4.26 (95% CI 1.92-9.49) and 7.89 (95% CI 3.73-16.66), 
respectively. Guo et al, in a single-center retrospective analysis of 187 COVID-19 patients, 
studied the relationship of baseline troponin levels and other comorbidities with mortality.6 
They reported that the risk of death can be stratified according to the presence of elevated 
troponin and/or previous history of cardiovascular disease. The risk of death in these patients 
increased linearly, with 7.62% of those dying with no history of cardiovascular disease 
compared with 13.3% of those with presence of only previous history of cardiovascular 
disease, 37.5% in those with presence of elevated troponin levels only, and 69.4% in those 
with both elevated troponin levels and history of cardiovascular disease. Notably, elevated 
troponin level carried a strong prognostic value even in the absence of cardiovascular disease 
history. In addition, the authors reported that in survivors, during the hospitalization period, 
the troponin levels remained stable and within normal limits. On the other hand, non-
survivors showed a trend of gradual and progressive increase in troponin levels. This suggests 
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that troponin elevation may reflect progression of the disease to a severe stage,12 notably 
through a continual inflammatory surge.  
If troponin elevation occurs in the absence of clinical symptoms, ECG changes and 
other indications, extensive investigations such as echocardiography and coronary 
angiography are not recommended routinely to exclude acute coronary event. Similarly, 
while it is crucial to ensure adherence to long-term prescribed cardiovascular therapies, it is 
unclear whether isolated elevation of troponin warrants any cardiovascular therapy. This 
topic is discussed extensively in a separate section. 
In conclusion, elevated troponin levels are frequently seen in patients with COVID-19 
disease. The reasons are multifactorial, and routine causes should be excluded in the first 
step.  In the absence of specific etiology, SARS-CoV-2 infection induced inflammation with 
myocardial injury may be the cause. Elevated troponin levels are associated with higher risk 
of severe disease and death. Several gaps in knowledge persists, and it will be interesting to 
evaluate whether there is a linear association of troponin levels with risk of death, after 
adjusting for other confounders and elevated inflammatory response. Mechanistic studies are 
needed to evaluate for the cause of myocardial injury, and whether there is a potential 
therapeutic option available. The role of troponin as a prognostic factor and in stratification 
of risk needs further elaboration.13 
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Figure 1: Etiology of troponin elevation in patients with SARS-COV-2 infection and its 
prognostic implication 
 
AMI: Acute myocardial infarction, PE: pulmonary embolism, AHF: acute heart failure, MI: 
myocardial infarction, ICU: intensive care unit 
 
COVID-19 and Hypertension 
Take Home Points: 
• Hypertension is associated with a higher risk of severe COVID-19 disease and greater 
mortality rates. 
• Until further studies reveal the impact of pre-existing or de novo RAS blockade on 
COVID-19 disease progression or severity, there is no justification to omit RAS blockers in 
COVID-19 patients.  
Research questions 
• What is the association of a pre-existing hypertension diagnosis and/or blood pressure 
level itself, with COVID-19 susceptibility and prognosis in fully adjusted analyses? 
• What is the association of pre-existing or de novo RAS blockade with COVID-19 
outcomes in both hypertensive and non-hypertensive patients? 
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Early, epidemiological analyses have suggested an association between COVID-19 disease 
(and its associated mortality) and cardiovascular risk factors, such as hypertension. This 
focused section summarizes current understanding and key missing information regarding 
hypertension and COVID-19 disease. 
SARS-CoV-2, similar to SARS-CoV that caused severe acute respiratory syndrome  (SARS) 
in 2003, enters cells through an endosomal pathway, with its spike protein binding to 
angiotensin-converting enzyme 2 (ACE2).14 ACE2 is a mono-carboxypeptidase which 
cleaves and generates several peptides within the renin–angiotensin system (RAS), including 
angiotensin II (AngII).  It is widely expressed in different tissues including lungs, heart and 
kidneys and SARS-Cov-2 internalization down-regulates surface expression of ACE2, 
resulting in increased AngII signaling. While animal models have shown that ACE inhibitors 
(ACEi) and angiotensin receptor blockers (ARBs) can increase ACE2 tissue mRNA levels, 
poor evidence exists in human tissues and there are no consistent clinical data.  RAS is 
fundamental in the pathogenesis and continuation of human hypertension (and as a target for 
first-line therapeutics) and therefore, concern has arisen regarding the possibility of 
hypertension as a risk factor for, and predictor of, negative outcomes with COVID-19. 
Furthermore, scrutiny has been placed on the widespread concomitant use of RAS drugs 
(such as ACEi and ARBs) in patients with CVD and/or hypertension and the effects thereof 
on outcomes from COVID-19 disease. 
Various reports have shown that between 15-35% of patients with COVID-19 have 
coexisting hypertension15, 16 (Table 1).  A meta-analysis of 8 recent reports, including 46248 
confirmed COVID-19 patients, suggests that hypertension is the most common comorbidity 
(18%) seen in these patients.26 Similar relationships between pre-existing hypertension and 
other novel coronavirus infections such as Severe Acute Respiratory Syndrome (SARS) and 
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Middle East Respiratory Syndrome (MERS) have been identified previously. For example, 
meta-analysis of >600 MERS cases revealed hypertension prevalence of up to 50%;27 thus so 
far, the prevalence of hypertension in the COVID-19 pandemic appears to be lower.  
This apparent association of COVID-19 with hypertension could be confounded by two 
factors: a) the high prevalence of hypertension in the general population, as in China at least 
23% of the adult population is hypertensive;28 and b) the association of hospitalized COVID-
19 patients with age.  For example, in a study on 191 COVID-19 patients (30% of them 
hypertensive), after multivariable adjustments for all other demographic and clinical 
parameters, hypertension was no longer an independent risk factor.2 
A background of hypertension seems to correlate with severity of the disease and mortality. 
Wu et al. found that, among COVID-19 patients, hypertension was twice more common in 
those with Acute respiratory distress syndrome (ARDS) and, among these, more common 
among those who died  (HR 1.82 and 1.70, respectively).18 A review of 3200 Italian COVID-
19 hospital deaths reported hypertension was present in 73.8 % of cases.29 In another large 
study, hypertension was an independent risk factor, associated with 50% excess risk of ICU 
admission or death even after controlling for age and smoking status.19 
It is unclear how hypertension itself, or blood pressure level, could correlate with severity of 
COVID-19 disease. Some hypertensive patients may have high ACE2 tissue expression (thus 
facilitating the virus entry in target cells), to counteract RAS activation and high Ang II level 
(latter contributes to the lung injury with inflammation and fibrosis and also causes direct 
myocardial damage.30 
Indeed, if the above hypothesis is true then it is possible that ARBs may be 
protective.31, 32 Recent retrospective data may be consistent with this hypothesis.33 In this 
study, the use of ARBs in hypertensive patients with COVID-19 was associated with lower 
risk of adverse outcomes (OR of severe disease=0·343). Another study in their retrospective 
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evaluation reported that amongst COVID-19 patients, those with hypertension and on ACEi 
or ARB treatment (compared to the hypertensive patients on other treatments) were 
associated with numerically lower ICU admissions and deaths.34 However, both reports are 
retrospective and have not had a peer-review yet (pre-prints), and clearly have several issues 
with confounding and bias. Pending further evidence, for now,  it is difficult to be certain in 
which direction co-existent treatment with ARBs or even starting ARBs de novo would lead 
to in COVID-19 disease given the potential opposing effects of ACE2 upregulation on viral 
entry and RAS blockade preventing further lung and cardiac injury. This is under 
investigation in at least one RCT (NCT04312009). To date, all international hypertension and 
cardiac societies have recommended continuation of RAS drugs in COVID-19 disease in 
patients with CVD and/or hypertension.  
The current knowledge gap regarding the role of hypertension as a risk factor independent 
from age or other comorbidities will require large epidemiological studies including non-
hospitalized patients with milder forms of COVID-19 infections, and a comparison with the 
prevalence in the general population, which may also reveal the impact of concomitant RAS 
blocking drugs on infection incidence and progression. There is currently a knowledge gap 
regarding both the effect of human RAS blockade on ACE2 expression and on the effect of 
ACE2 or other RAS genotype (i.e. low renin status) variations that may alter angiotensin II 
levels, and thereby predispose to viral infection and/or to more severe lung disease. Another 
question that needs further elaboration is whether prevalent BP level per se has an 
independent role on severity of infection or not. Lastly, the impact of RAS blocking drugs in 
COVID-19 affected patients with or without hypertension needs to be urgently investigated.   
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Table 1. Prevalence of hypertension in case series studies of Patients with COVID-19 
disease 
Article 
Total 
number of 
patients 
Proportion (%) 
of patients 
with HT at 
baseline 
Proportion 
(%) of 
those in 
ICU with 
HT  
Proportion (%) of 
those with severe 
disease or ARDS 
with HT 
Deaths (%) 
amongst those 
with HT 
Composite 
(%)  
of death, ICU 
admission or 
intubation in 
those with HT 
Notes 
Huang C et 
al.12 
41 15% 15% - - - 
Two-thirds were 
exposed to the 
Huanan seafood 
market 
Zang J et al.17 140 30% - 37.9% - - 
Severe vs non 
severe disease 
Wu C et al.18 
 
201 19.4% - 27.4% 36.4% - 
ARDS and 
Deaths 
Shi S et al.7 
 
416 30.5% - - -  
Cardiac injury 
and mortality 
Guan W et 
al.19 
 
1590 16.9% - 32.7% - 35.8% 
Comorbidities 
and outcomes 
Chen T et 
al.20 
 
274 34% - - 48% - 
Clinical 
characteristics of 
deceased patients 
Guan W et 
al.15 
 
1099 15% - 23.7% - 35.8% 
Patients across 
Mainland China 
Wang et al.5 138 31.2% 58.2% - - - 
Critically ill vs 
non-critically ill 
patients  
Liu K et al.21 
 
137 9.5% - - - - 
Patients admitted 
in 9 tertiary 
hospitals in 
Hubei Province  
(Dec 2019-Jan 
2020) 
Du Y et al.22 
 
85 - - - 37.6% - 
Clinical features 
of fatal cases  
Wang L et 
al.23 
339 40.8% - - 50% - 
Consecutive 
cases over 60 
years old 
Zhou F et al.2 191 30% - - 48% - 
Risk factors 
associated to in-
hospital death. 
Mo P et al.24 
 
155 23.9% - - - - 
Study on 
refractory 
COVID-19 
patients 
Cao J et al.25 102 27.5% - - 64.7% - 
Short-term 
outcomes  
Summary 
(total/mean[S
D]) 
4908 24.9 [9.1%] 36.5% 30.4 [6.2]% 47.4 [10.2]% 35.8%  
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HT: hypertension. ARDS: Acute Respiratory Distress Syndrome. ICU: Intensive Care Unit SD: 
standard deviation 
 
COVID-19 infection and the risk of vascular events 
Take Home Points 
• Vascular events appear to be a common complication of COVID-19 infection. 
• The increased burden of vascular comorbidities among people with severe infection is 
only a partial explanation or such increased risk of events. 
 
As the COVID-19 pandemic strains the medical system of the United States and other 
countries, there exists a need to understand the cause of inpatient mortality in this population. 
The risk of severe COVID-19 is associated with older age and cardiovascular comorbidities 
including hypertension, coronary artery disease, stroke, and diabetes mellitus.2 Additionally, 
COVID-19 may in turn cause cardiovascular disease. The SARS-CoV-2 utilizes the ACE2 
receptor to enter cells, which is highly expressed in the heart, potentially explaining the 
increased risk of poor outcomes among people with cardiovascular disease (CVD) as well as 
increasing the risk of myocardial injury and cardiovascular disease after infection. Recent 
reports indicate up to 22% of COVID-19 patients who required ICU care had evidence of 
myocardial injury, and 12% of patients who did not have prior CVD had elevated troponin 
levels or cardiac arrest during their hospitalization.3 Acute cardiac injury is a predictor of 
mortality and occurs in a significant proportion of COVID-19 patients.3 In a study of 187 
patients confirmed to have COVID-19, a third of the patients had prior cardiovascular 
disease. There exists a biological gradient between history of prior cardiac disease and 
plasma evidence of T-troponin including a much higher mortality noted among patients with 
elevated plasma levels of T-troponin and prior cardiovascular disease.6 Interestingly, in this 
study there was a linear association between elevated troponin levels and the inflammatory 
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biomarker C-reactive protein. Increased levels of T-troponin, leukocytosis and elevated D-
dimer are markers of increased mortality in this population.20 To date, there is one study on 
risk of stroke after COVID-19.35 Stroke occurred in ~6% of severe COVID-19 patients, and 
patients with cardiovascular disease were at higher risk for stroke after COVID-19, similar to 
other studies on stroke risk after infections. 
There is a paucity of good quality data regarding the rates of vascular disease in the 
setting of acute COVID-19 infection. A small case series from Washington state reported that 
up to one third of those severely affected with COVID-19 had an acute vascular event.36 To 
date, among the 932 deaths from COVID-19 in New York City (NYC), 748 patients had an 
underlying illness including diabetes, lung disease, cancer, immunodeficiency, heart disease, 
hypertension, asthma, kidney disease, and GI/liver disease. One of our top priorities is to 
investigate the predictors and rates of vascular events in NYC, given the increased risk of 
death among COVID-19 patients with vascular events and the unfortunate role of NYC as the 
latest epicenter of the pandemic in the world. 
Infections have long been identified as risk factors and/or triggers for stroke and 
myocardial infarction (MI).  The role of sepsis as a risk factor for stroke, myocardial 
infarction, and new-onset atrial fibrillation has been described, and illustrated that patients 
with concomitant coagulopathy, congestive heart failure, renal failure and other circulation 
disorders had increased the risk of stroke after sepsis with the risk remaining up to a year 
after the sepsis event.37 More common infections, such as respiratory tract infections or 
influenza-like illness (ILI), have been identified as both a potential chronic risk factor and an 
acute trigger for stroke and myocardial infarction.  Moreover, risk of infections and stroke/MI 
share several similarities. First, endothelial dysfunction plays an important role in both stroke 
and sepsis pathophysiology.38 Second, higher baseline biomarkers of inflammation are related 
to both an increased risk of infections and stroke.39, 40 Third, independent risk factors for 
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stroke are similar to independent risk factors for infections, with increased inflammatory 
biomarker activity during a baseline stable phase of health associated with future risk of both 
stroke and sepsis.39, 40 
The data so far available for acute COVID-19 infection suggests a role for acute 
systemic inflammation in the pathophysiology of the myocardial injury. The inflammatory 
response to the virus causes an acute influx of inflammatory cytokines, which in turn 
activates the endothelium and may cause widespread vascular damage.41 At this time, there 
seem to be two patterns of myocardial injury with COVID-19: cytokine storm mediated or 
secondary hemophagocytic lymphohistiocytosis vs viral myocarditis or stress 
cardiomyopathy.42 The specific mechanism of cardiac involvement is also still under 
investigation, but is potentially ACE2 mediated. It is imperative to better understand the 
pathophysiology of COVID-19-related vascular events so that adequate therapies may be 
implemented to curb the associated vascular morbidity and mortality.  
COVID-19 and myocardial injury: possible mechanisms  
Take Home Point 
• Broad elevations of chemokines and cytokines occur in SARS-CoV2 infection, similar 
to cytokine release syndrome (CRS) seen in cancer patients on immune-modulating therapy. 
Yet, some overlap with troponin elevation has been seen. 
Research Questions 
Could the elevation in inflammatory markers (ex. IL-6) play a role in COVID-19 associated 
cardiac toxicity. And if so, could this be a potential target for treatment? 
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A growing number of reports have described cardiac injury, absent of coronary obstruction, 
during severe COVID-19 infection.43, 44 In a recent single-center study of 416 patients with 
confirmed COVID-19, cardiac troponin I (cTnI) elevation was seen in 19.7% and corresponded 
to higher in-hospital mortality.7 Similarly, in another study of 187 confirmed COVID-19 
patients, 52 (27.8%) had evidence of myocardial injury, reflected by elevated troponin-T.6 In 
addition to elevations in troponin, a study of 138 hospitalized COVID-19 patients also revealed 
a high prevalence of arrhythmias, occurring in 16.7% (23) of patients.5 Despite these 
observations, the exact mechanism(s) by which COVID-19 induces cardiac damage (Figure 2) 
remain unclear.  
Viral myocarditis with inflammatory infiltrates or myocyte necrosis and injury by a systemic 
inflammatory response (SIRS) have been implicated as potential causes of cardiac injury. 
Here, we used the criteria for clinically suspected myocarditis by the ESC45 for a critical 
appraisal of reports on cardiac injury by SARS, MERS and other coronavirus infections as 
well as emerging data on COVID-19. Moreover, we discuss the concept of broad systemic 
inflammatory response as an alternative or additional mechanism for myocardial injury in 
COVID-19. 
Coronaviruses are not regarded as cardiotrophic viruses, and reports on cardiac 
involvement with coronavirus-induced respiratory illness are rare. The criteria for clinically 
suspected myocarditis were met in one patient with coronavirus OC43 infection (chest pain, 
ECG changes, pericardial effusion, Table 2).46 In one patient with MERS who presented with 
chest pain and dyspnea, the diagnosis was corroborated by elevated cardiac biomarkers, 
diagnostic ECG changes and findings by echocardiography and CMR.47 Of note, LV 
dysfunction persisted at three months after diagnosis. In the literature on SARS, we identified 
no cases of myocarditis or evidence of other major cardiac involvement. In one SARS patient 
with LV dysfunction, myocyte necrosis or inflammatory infiltrates was absent at autopsy,48 
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whereas SARS-CoV RNA and macrophages were detected in 7 out 20 autopsy samples in 
another report.49 
The two viruses causing SARS (SARS-CoV) and COVID-19 (SARS-CoV2), both 
attach to ACE2 as the cellular entry receptor.14 It may be reasonable to postulate that those 
with elevated ACE2 receptors are at increased risk for infection and more severe disease 
response, including arrhythmic events. In most studies on COVID-19, cardiac injury was 
defined by lab parameters, such as troponin and creatinine kinase-MB. As of this writing, few 
studies have reported additional ECG or cardiac imaging data needed to apply of the ESC 
criteria. So far, two cases of myocarditis have been reported, each supported by biomarkers, 
LV dysfunction with pericardial effusion and normal coronary anatomy.43, 44 The patients 
symptomatically improved on guideline-directed heart failure treatment. No substantial 
pathology was seen in the myocardium of another patient at autopsy,50 raising concerns over 
this hypothesized mechanism of COVID-associated myocardial injury.  
Concurrently, increasing data have shown the presence of a broad systemic 
inflammatory response after COVID-19 confirmation.50–53 Notably, similar presentations 
have been observed among cancer patients with cytokine release syndrome (CRS) following 
initiation of novel immune-modulating therapies, even manifesting with heart failure and 
arrhythmias.54, 55 In these patients, high levels of circulating cytokines, including IL-6 have 
been observed.55 In patients with severe CRS, elevation of ACE2 and other markers (ex. 
interferon) have been linked to organ toxicity manifestations.56 Among COVID-19 patients, 
broad elevation of chemokines and cytokines have also been reported, with emerging reports 
suggesting potential efficacy with IL-6 blockade after infection.57, 58 In accordance to a Phase 
III study, randomizing patients to the IL-6 receptor antagonist, Tocilizumab, after COVID-19 
infection is currently underway.59 These observations raise the potential that much of the 
troponin release may actually be driven by a broader inflammatory response.  
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In summary, the pathophysiology of COVID-19 induced cardiac clinical manifestations 
remains unknown, and may relate to a direct viral-induced myocarditis, a broader systemic 
inflammatory response, or even another process not described here such as hypoxia or 
catecholamine induced cardiac injury. Given the tsunami of COVID-19 infections and the 
potential profound implications on cardiovascular health, additional studies are needed. 
 
 Figure 2. Balance of the evidence to guide current understanding of mechanisms of clinical 
cardiac events after COVID-19 infection. 
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Table 2. Coronavirus-associated myocarditis. 
Author Year Age/Sex Symptoms Cardiac 
biomarkers 
ECG Imaging Virology 
Riski46 1980 46/male Chest pain, 
fatigue 
Not provided ST 
elevations,  
T wave 
inversions 
Pericardial 
effusion 
(TTE) 
CoV 
OC43 
titer 
Alhogbani47 2016 60/male Chest pain, 
fever, 
dyspnea 
Troponin-T, 
proNT-BNP 
Sinus 
tachycardia 
with T wave 
inversions 
Severely 
decreased 
LVEF, 
pericardial 
effusion 
(TTE); 
LGE and 
T2w images: 
interstitial 
edema 
(CMR) 
MERS  
sputum 
RT-PCR  
Hu43 2020 37/male Chest pain, 
diarrhea, 
dyspnea 
Troponin-T, 
CK-MB, 
BNP 
Inferior ST 
elevations 
LVEF 27%, 
pericardial 
effusion 
(TTE) 
SARS-
CoV2 
sputum 
RT-PCR  
Inciardi44 2020 53/female Fatigue, 
fever, 
cough 
Troponin-T, 
proNT-BNP 
Diffuse ST 
elevations 
LVEF 27%, 
biventricular 
diffuse 
hypokinesis 
(TTE); 
LGE andT2w 
images: 
interstitial 
edema 
(CMR) 
 
SARS-
CoV2 
sputum 
RT-PCR 
TTE = transthoracic echocardiogram; CMR = cardiac MRI; LGE = late gadolinium 
enhancement 
 
 
COVID-19 and cardiac arrhythmias 
Take Home Points 
• COVID-19 is associated with a high inflammatory burden that may cause arrhythmias 
due to increased metabolic demand, hypoxia and/or sympathetic stimulation in patients with 
and without pre-existing cardiovascular disease. 
• New-onset ventricular arrhythmias combined with elevated troponin-T levels in the 
setting of COVID-19 should raise suspicion of myocarditis. 
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• Antiviral therapy for COVID-19 may lead to electrical disturbances (most often QTc 
prolongation) and increased arrhythmic risk. 
 
While cardiovascular complications of COVID-19 are increasingly recognized, the incidence 
of cardiac arrhythmias in affected patients is infrequently reported. Given the paucity of data, 
it is tempting to assess precedent among similar viruses including severe acute respiratory 
syndrome (SARS) coronavirus (SARS-CoV). Yu et al described that 87 (72%) of 121 
hospitalized SARS-CoV patients had tachycardia which could not be solely explained by 
hypotension, while transient bradycardia occurred in 18 (15%) patients.60 Apart from one 
patient with atrial fibrillation, no arrhythmias were observed, but the cohort existed mostly of 
relatively young (mean age 38 years) and healthy healthcare workers. For COVID-19 (SARS-
CoV-2), a literature search to determine the prevalence of arrhythmias yielded three reports 
(date of search 4 April, 2020), which are summarized in Table 3. All studies were retrospective 
case series in hospital settings in China, with arrhythmias reported in 6-60% of patients. Wang 
et al were the first to report that 23 (17%) of 138 COVID-19 patients developed arrhythmias, 
although the types of arrhythmia were not specified.5 In addition, these authors showed that 16 
(44%) of 36 intensive care unit admissions experienced arrhythmias as complication. A lower 
prevalence of arrhythmias was reported by Guo et al, who showed that 11 (6%) of 187 COVID-
19 patients developed ventricular tachycardia or fibrillation, most often (n=9/11) in the setting 
of myocardial injury (defined as troponin-T >99th percentile of normal).6 Indeed, it seems likely 
that the occurrence of arrhythmias is related to severity of disease, as the proportion of patients 
with reported arrhythmias was much higher (n=51, 60%) in a study of 85 fatal COVID-19 
cases.22 Of note, none of these reports compare the prevalence of arrhythmias among 
cardiovascular disease-naïve versus cardiac comorbid patients. 
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As with all viral infections, the high inflammatory burden caused by COVID-19 
stresses the heart and vascular system. This leads to increased metabolic demand, hypoxia, and 
neurohumoral stress, which (alone or in combination) may trigger arrhythmias. In addition to 
such “indirect” pro-arrhythmic effects, COVID-19 infection may also directly affect the 
myocardium. For instance, COVID-19 induced myocarditis may set the stage for arrhythmias; 
the latter may also occur in the absence of overt respiratory failure, i.e. either in the initial phase 
of the disease or after improvement of respiratory failure. Indeed, some publications have 
reported sudden cardiac arrest early in the disease course (e.g. immediately after hospital 
admission),4 and anecdotal reports in the media describe relatively young and healthy 
individuals who died suddenly and were later found to test positive for SARS-CoV-2. Whether 
these sudden deaths are the consequence of myocarditis, other COVID-19 related effects on 
the heart, or e.g. massive pulmonary embolism, remains elusive. In rare cases, it is possible 
that the presence of SARS-CoV-2 uncovers an underlying cardiac condition. For instance, 
fever associated with COVID-19 infection may unmask Brugada syndrome, an inherited 
disorder associated with increased arrhythmia risk.61 Accordingly, specific COVID-19 related 
recommendations have been proposed for patients with inherited arrhythmia syndromes.62 
Lastly, several of the proposed drugs for COVID-19 have pro-arrhythmic potential. In 
addition to a modest effect on the QT-interval and increased risk of torsades de pointes, 
(hydroxy)chloroquine may induce conduction abnormalities, particularly AV-conduction 
problems which may be consequent to sodium channel inhibition.63 Lopinavir/ritonavir is also 
reported to potentially affect repolarization, although QT prolongation was only rarely 
observed (n=1/99, 1%) in a recent open-label trial in COVID-19 patients.64 Nonetheless, both 
(hydroxy)chloroquine and lopinavir/ritonavir should be avoided in patients with congenital or 
acquired long QT syndrome, and particular care should be taken to prevent electrolyte 
disturbances (especially hypokalemia) and the concomitant use of other QT-interval 
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prolonging drugs.62 The combination of (hydroxy)chloroquine with azithromycin or 
lopinavir/ritonavir may prove particularly harmful since these all inhibit CYP3A4 and 
potentially affect (hydroxy)chloroquine metabolism. In addition, other proposed drugs for 
COVID-19 such as remdesivir, interferon, and ribavarine may have cardiac side-effects.65 
Given that the level of evidence for a potential beneficial effect of these drugs in COVID-19 
patients is as yet limited, caution should be exercised when prescribing these medications to 
those with pre-existing cardiovascular disease. 
Table 3. Summary of clinical reports describing arrhythmias in COVID-19 patients. Search 
strategy: (“SARS-CoV-2” OR “COVID-19” OR “novel coronavirus”) AND (“arrhythmia” 
OR “tachycardia” OR “bradycardia” OR “cardiac arrest”), date of search 4 April 2020.  
Reference 
 
Location Type of study Setting N N with 
arrhythmia 
Remarks 
Guo et al6 
 
Wuhan, 
China 
Single-center 
retrospective 
case series 
Hospitalized 
patients 
187 11 (6%) 
VT/VF 
Only VT/VF reported. Almost 
all (9/11 patients with VT/VF) 
had increased troponin-T levels.  
Du et al22 Wuhan, 
China 
Multi-center 
retrospective 
case series 
Fatal cases 85 51 (60%) 
type of 
arrhythmia 
unknown 
Report on 85 fatal cases. No 
information on type of 
arrhythmia. 
Wang et al5 Wuhan, 
China 
Single-center 
retrospective 
case series 
Hospitalized 
patients 
138 23 (17%) 
type of 
arrhythmia 
unknown 
No information on type of 
arrhythmia. Arrhythmic 
occurrence relates to severity of 
disease: 44% of 36 ICU patients 
had arrhythmias.  
ICU: intensive care unit, VF: ventricular fibrillation, VT: ventricular tachycardia 
 
COVID-19 and the use of statin and other cardiovascular protective therapies  
Take Home Points 
• A significant proportion of patients with COVID-19 have evidence of myocardial 
injury, which portends a higher risk of ICU admission and death.  
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• All patients with COVID-19, where clinically indicated, should be commenced on 
statins and antiplatelet therapy, if not already on them. Currently, there is no evidence to stop 
cardioprotective therapy, assuming no contra-indications.   
Research questions: 
• Is there a role for early use of the cardioprotective therapies in patients with COVID-
19 who have either cardiovascular risk factors or evidence of myocardial injury? 
• What is the pathophysiology of troponin rise in the patients with COVID-19? - is there 
an argument for increased plaque rupture and microvascular thrombosis, on top of the 
hypothesized direct myocardial infiltration and inflammation? 
 
Early observations from China found a higher prevalence of cardiovascular comorbidities 
among non-survivors and patients requiring ICU, with hypertension, diabetes and cardio-
cerebrovascular disease increasing overall case fatality rates (CFR) of 2.3% to 6%, 7.3% and 
10.5% respectively.66 Other studies suggest that serum troponin is an independent predictor of 
prognosis, showing patients with pre-existing cardiovascular disease but normal troponins had 
lower mortality rate (13.3%) compared to patients with no known cardiovascular comorbidities 
and elevated troponin (37.5%).6 A review of serum troponin in critically ill patients with a wide 
range of presentations previously suggested an association between elevated serum troponin 
and increased mortality (OR 2.5, CI 1.9-3.4, p<0.001) and length of ICU stay.67 A list of 
published studies suggesting myocardial injury in patients with COVID-19 is summarized in 
Table 4.2, 4–7, 12, 20, 68 
Whilst it is reasonable to assume that patients with pre-existing cardiovascular co-
morbidities are more susceptible to COVID-19 related myocardial injury, only 30% and 15% 
of patients with cardiac injury had coronary heart disease and chronic heart failure, 
respectively.7 This suggests that the elevated troponin may be a marker of overall disease 
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severity, regardless of underlying cardiovascular status. Data is lacking in this regard as less 
than 27% of patients with troponin elevation had electrocardiograms (ECGs) in one study,7 and 
there are few studies linking imaging correlates of myocardial injury (echocardiography, 
cardiac magnetic resonance) with troponin elevation.43, 44 Troponin elevation itself also 
correlated strongly with other systemic inflammatory markers such as interleukin-6, C-reactive 
protein, ferritin as well as aggressive disease on chest radiography, findings which support the 
notion that troponin may be one of many markers of disease severity.  
Further, there is accumulating evidence that patients with severe COVID-19 may have 
a cytokine storm syndrome and that mortality may be due to virally driven hyperinflammation. 
This is supported by observations of patients admitted to ICU recording higher plasma cytokine 
levels including interleukin (IL)-2, IL-7, IL-10 and granulocyte-colony stimulating factor 
(GCSF).12 The close correlation between troponin levels, inflammatory markers and 
triglyceride levels (akin to secondary haemophagocytic lymphangiohistiocytosis) may support 
indirect effect of SARS-CoV-2 on the myocardium through immune-mediated mechanisms. 
Whether there is a role for standard therapies for troponin elevation such as statin or dual 
antiplatelet therapy is unknown. 
Development of new therapeutic agents to a novel disease such as COVID-19 is 
unrealistic in a timely manner. Instead, many have used existing pharmaceuticals such as 
corticosteroids, hydroxychloroquine, azithromycin and tocilizumab, primarily addressing the 
systemic inflammatory response. Given that myocardial injury is a strong predictor of severe 
disease, one may reasonably consider maximal optimization of treatment options, particularly 
in those with previous cardiovascular disease or who at a higher cardiovascular risk, as a 
potential therapeutic target. To date, there is no evidence on the effect of statins in COVID-19 
independent of CAD or otherwise. One possible mechanism for myocardial injury in COVID-
19 could be through plaque instability and rupture triggered by the profound cytokine activity 
D
ow
nloaded from
 http://ahajournals.org by on May 1, 2020
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved 
 
and inflammation. Past clinical trials have shown that statins reduce cardiovascular events, with 
evidence suggesting this is mediated through reduction of inflammation and plaque 
stabilization.69, 70 That may suggest a preventative role of statin therapy. 
From a theoretical perspective, statins play a role in regulating the innate immune 
response through post-translational modification of intracellular signaling molecules. This 
leads to suppression of the transcription factor NFkB, decreased chemokine levels including 
IL-1β, TNFα, IL-6 and decreased monocyte activation.71 This reduces inflammatory cell 
infiltrates and macrophage accumulation in atherosclerotic plaques. This is relevant in SARS-
like infections, which pre-clinically seem to upregulate a pro-inflammatory gene, MYD88 
which results in activation of the NFkB pathway leading to marked inflammation. Transgenic 
mice with an attenuated NFκB pathway were more likely to survive a SARS infection. Statins 
play a role in regulating MYD88 expression levels in stress conditions and early, high dose 
statins appeared to suppress NF-kB activation.72 However, the use of statins in COVID-19 
without any obvious clinical indication may be problematic, given its interactions with 
supportive treatment, including macrolides and potential antiretrovirals, such as lopinavir and 
ritonavir combination.  
The increased risk of plaque rupture in severe illness poses the question if ant iplatelets 
and other cardioprotective therapies such as beta-blockers are beneficial. A retrospective study 
including 20,000 patients in ICUs showed that patients taking aspirin, beta-blockers and/or 
statins had a 30-day mortality reduction in a troponin-dependent fashion. In particular, aspirin 
and beta-blockers reduced 30-day mortality only if the serum troponin was elevated.73 The 
utility of continuation or de-novo commencement of RAS blockers in these patients have been 
discussed in the section on hypertension in this manuscript.  
There have been reports of COVID-19 patients presenting with chest pain and dyspnoea 
with ST-segment elevation on electrocardiography, later found to have non-obstructed 
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coronary arteries. This has led to the proposition of widespread microvascular thrombosis 
although myocarditis remains a possibility.43, 44 The role of aspirin and beta-blocker in 
fulminant myocarditis is however, conflicting. Historic experimental data have shown selected 
beta-blockers were cardioprotective through suppression of inflammatory cytokines in 
autoimmune myocarditis, whilst others had deleterious effects.74  
Indeed, studies have suggested high levels of D-dimer (>1 µg/ml) are associated with 
higher mortality risk indicating a hypercoagulable state.2 This is supported by findings of small 
vessel lumen stenosis and occlusion on lung dissections in COVID-19 patients.75 Further, a 
recent retrospective study found better prognosis associated with heparin anticoagulation.76 
However, whether there is a similar role of oral anticoagulants and/ or antiplatelets in those 
with  less severe disease, who are treated in outpatient or ambulatory settings, is unknown. 
In summary, we need a better understanding of the mechanisms underlying cardiac injury in 
COVID-19. Further histo-pathological studies may distinguish between plaque rupture, 
microvascular thrombosis or direct myocardial infiltration and inflammation as a cause of 
troponin elevation. Moving forward, prospective, randomized clinical trials are needed to 
determine the role of cardioprotective therapies and anticoagulation in COVID-19 patients.  
Pending these, patients on pre-existing cardioprotective therapies should continue on them if 
possible. Patients with COVID-19 who meet conventional indications for these cardiovascular 
therapies should be commenced on them in the absence of contraindications. At present, there 
is no data to support expanding the role of these protective therapies to other COVID-19 
patients, but that may change with rapidly evolving studies.
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Table 4: Summary of studies showing the evidence of myocardial injury in COVID-19 patients, 
and subsequent outcomes. 
 
Article 
 
Total 
number 
patients 
Median 
[Mean] 
age 
(years) 
Proportion 
(%) of 
patients with 
the evidence 
of 
myocardial 
injury  
Overall 
Death (%) 
Patients with raised troponin 
N (%) 
Death categorized by troponin level 
N (%) 
Non-ICU / 
Survivors♯ 
ICU/Non-
Survivors♯ 
Normal Elevated 
Huang 
et al.12 
41 49 5 (12.0)* 6 (15.0) 1/28 (4) 4/13 (31) NA NA  
Zhou et 
al.2 
191 56 24 (17.0) 54 (28.0) 1/95 (1)♯ 23/50 (46) ♯ NA NA 
Wang et 
al.5 
138 56 10 (7.2) 6 (4.3) 2/102 (2) 8/36 (22) NA NA 
Zhang et 
al.68 
48 [71] 13 (27.1) 17 (35.4) 3/31 (9.7) ♯ 10/17 (59) ♯ NA NA 
Yang et 
al.4 
52 [60] 12 (23.0) 32 (61.5) 3/20 (15) 9/32 (28) NA NA 
Chen et 
al.20 
274 62 83/203 
(41.0)** 
113 (41.2) 15/109 (14) 68/94 (72) NA NA 
Shi et 
al.7 
416 64 82 (19.7) 57 (13.7) NA NA 15 (5) 42 (51) 
Guo et 
al6 
187 [59] 52 (27.8) 43 (21.0) NA NA 12 (9) 31 (60) 
 
*defined as hypersensitive troponin I >28pg/ml or new abnormalities on ECG or ECHO 
** defined as >15.6 pg/mL 
♯ survivors or non-survivors 
NA: not available;  NB: most proportion are rounded off to the nearest integer 
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Acute Coronary Syndrome in the COVID-19 Pandemic Era: how to triage and when to 
resort to invasive strategies 
Take Home Points: 
• Timely primary percutaneous coronary intervention (PCI) remains the mainstay treatment 
for ST-elevation myocardial infarction (STEMI).  
• In case of patient- or system-related delays in mechanical reperfusion in the 
contemporary COVID-19 era, fibrinolytic therapy within door-to-balloon of 30 minutes may be 
an alternative treatment for STEMI in the absence of contraindications. 
• An invasive strategy is highly recommended for patients with non-ST-elevation acute 
coronary syndrome (NTE-ACS) who are at high risk.  
• In the COVID-19 era, and especially when the local community outbreak is increasing 
and the healthcare system is overwhelmed, moderate- and low-risk patients with NSTE-ACS can 
be treated with an ischemia-guided approach. 
 
Acute coronary syndromes (ACS) encompass a spectrum of clinical entities ranging from ST-
elevation myocardial infarction (STEMI) to non-ST-elevation myocardial infarction and unstable 
angina. The latter two, often coined collectively as non-ST-elevation ACS (NSTE-ACS), differ 
in their pathophysiology from STEMI in that they predominantly result from an acute non-
occlusive thrombus overlying a disrupted plaque.77 On the other hand, STEMI is usually 
attributable to an acute thrombosis overlying a disrupted plaque, which is completely occlusive 
of the epicardial coronary artery.78 STEMI manifests with an acute myocardial injury pattern on 
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ECG and needs to be aborted immediately to prevent irreversible myocardial damage. Therefore, 
a timely reperfusion strategy is the mainstay treatment after STEMI.78 Of the two available 
reperfusion modalities, primary percutaneous coronary intervention (PCI) is preferable to 
fibrinolytic therapy because it is safer and more effective.79 On the other hand, moderate- and 
high-risk NSTE-ACS patients who are medically stabilized can be treated with an urgent - but 
not necessarily emergent - invasive strategy (i.e. coronary angiography with intent to 
revascularize).77 
The swiftly spreading COVID-19 pandemic in the United States is placing an 
unparalleled pressure on the healthcare system. There is currently a rapid depletion of resources 
in many medical centers including shortages of hospital and ICU beds, personal protective 
equipment (PPE), and even healthcare workers (HCWs). Hospitalized patients and HCWs are at 
increased risk of infection with SARS-CoV2. Revisiting the modality of reperfusion after 
STEMI and the merits of an invasive strategy and its timing after NSTE-ACS is therefore 
critically important.   
The initial assessment of any patient with suspected ACS should include a history, 
physical examination (PE) and a 12-lead ECG. Measurements of cardiac biomarkers of necrosis 
(e.g. Troponins) should be performed serially, but reperfusion therapy should be decided upfront 
based on the clinical presentation and ECG. In the COVID-19 era, a focused but meticulous 
history and PE should be conducted assuming that every patient may be – at a minimum - an 
asymptomatic SARS-CoV2 carrier.  
In the current section, we propose categorizing ACS patients into three categories: 
critically ill ACS patients and non-critically ill STEMI and NSTE-ACS patients. In the COVID-
19 era, triaging patients to optimal medical therapy (OMT) alone versus invasive approach 
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(added to OMT) will depend on many factors, including patients’ ACS category, their COVID-
19 status, and safety issues (e.g. PPE availability, shortage of HCWs). 
All ACS patients who are critically ill (e.g. cardiogenic shock, mechanical complications, 
refractory heart failure) should undergo emergent coronary angiography with intent to 
revascularize (Figure 3). In general, this life-saving strategy should take place irrespective of the 
patients’ COVID-19 status and other considerations.  
For STEMI patients who are not critically ill, timely primary PCI remains the treatment 
of choice (Figure 3). Mechanical reperfusion, within a first medical contact-to-device (FMC-
device) time of 90 minutes when presenting to a PCI-capable hospital, is highly recommended.80 
Timely reperfusion is critically important to salvaging myocardium. However, in a small cohort 
of 7 STEMI patients from Hong Kong undergoing primary PCI in the COVID-19 era, longer 
median times in all components of STEMI care were observed.81 Difficulty of achieving timely 
mechanical reperfusion, especially in geographies severely affected by COVID-19, should be 
recognized. 
Accordingly, it is reasonable to administer fibrinolytic therapy, in the absence of 
contraindications,82 to appropriate STEMI patients in COVID-19 affected communities (Figure 
3). This is particularly relevant to STEMI patients who do not have high-risk features and are 
either known or suspected to have COVID-19. A bedside echocardiogram can be readily 
available and will add incremental value for risk stratification. An example of a STEMI patient 
eligible for fibrinolytic would be the case of a COVID-19 (+) patient who is hemodynamically 
stable and who is presenting with ST elevation in aVL alone and echocardiographic evidence of 
small lateral hypokinesis. Experts from the Sichuan Provincial People’s Hospital in China 
proposed the use of fibrinolytic therapy in COVID-19 (+) patient who are presenting with 
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STEMI, are hemodynamically stable and have no contraindication to fibrinolysis.83 Fibrinolytic 
therapy is most effective when administered within the first 2-3 hours of symptom onset. When 
chosen, timely pharmacological reperfusion within door-to-needle (DNT) of 30 minutes and 
preferably using the newer generation tenecteplase (TNK), is recommended.80 In case of failed 
fibrinolytic reperfusion, rescue PCI is a reasonable subsequent strategy.84 As for STEMI patients 
presenting to non-PCI capable hospitals, timely pharmacologic reperfusion is strongly 
encouraged, especially when the receiving PCI center is tackling a COVID-19 surge. In our 
opinion, transfer of successfully reperfused STEMI patients to a PCI-capable hospital, as part of 
a pharmacoinvasive approach, should not be routinely implemented but rather individualized 
depending on many factors (e.g. status of the receiving hospital and outbreak in the community).    
For NSTE-ACS patients who are not critically ill, we believe the majority of those may 
be safely treated with an ischemia-guided strategy in the COVID-19 era (Figure 3). A routine 
invasive strategy is superior to an ischemia-guided strategy after NSTE-ACS and reduces the 
risk of recurrent MI.85 However, the largest benefit appears to be confined to high-risk patients, 
and only modest benefit was observed in moderate-risk patients.85 These studies were largely 
done more than a decade ago when dual antiplatelet therapy (especially the novel P2Y12 receptor 
inhibitors), intensive lipid lowering and OMT were not routinely implemented or available. We 
therefore believe that treating moderate-risk NSTE-ACS patients in COVID-19-affected medical 
communities with an ischemia-guided strategy is reasonable. All NSTE-ACS patients need to be 
risk stratified adequately using objective risk scores.86 Those treated with an ischemia-guided 
approach may cross over to an invasive strategy if they manifest significant spontaneous or 
provoked ischemia or become unstable despite OMT.87 On the other hand, high-risk NSTE-ACS 
patients should still receive an invasive strategy.85 An early invasive strategy within ≤ 24 hours is 
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preferred, as it usually reduces recurrent ischemia compared to a delayed invasive strategy.88 
This is best done if COVID-19 testing is achieved prior to the procedure. Otherwise, when high 
level of suspicion for COVID-19 exists, a delayed invasive strategy (24-72 hours) may be 
selectively implemented in a controlled setting until the test result is available.   
There are several considerations that need to be accounted for when entertaining invasive 
therapy in an ACS patient in the contemporary COVID-19 era. All patients should undergo 
clinical screening for COVID-19. Ideally, every ACS patient undergoing non-emergent invasive 
therapy should get tested for COVID-19 before the procedure. If not feasible, at least patients 
with high clinical suspicion should be tested. All procedures for patients with confirmed or 
suspected COVID-19 should be performed, if possible, in a dedicated/repurposed cardiac 
catheterization laboratory with optimal protection strategies for HCWs and patients.9 Evaluation 
of the patient’s airway should be assessed prior to transfer to the catheterization laboratory. In 
patients with concerning respiratory distress, intubation should be performed prior to arrival of 
the patient to the catheterization lab if possible.89 All patients should be outfitted with a 
facemask. Proper protection of HCWs with appropriate PPE is essential, including appropriate 
facemask (N95 respirator), face-shield or goggles for eye protection, and gowns.90 
When the healthcare setting is not safe for HCWs and patients (e.g. lack of PPE, shortage 
of ventilators), the risks and benefits of an invasive strategy should be revisited, irrespective of 
the ACS category. Members of the heart team should deliberate and engage the patient and 
family in a process of shared decision making and, if necessary, invoke the ethics committee. 
This also applies to critically ill patients whose instability is attributable to advanced COVID-19 
illness rather than the ACS itself, and in whom an invasive therapy is likely futile. 
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Overall, the aforementioned recommendations and proposed clinical algorithm provide 
general clinical guidance. In the absence of robust data specific to the COVID-19 era, they 
represent our opinion and complement guidance provided by other societies.9, 89 As such, they 
should be tailored to local medical institutions and communities. These recommendations are 
dynamic and should be constantly revised as the burden of the outbreak and the availability of 
resources continues to change over time. 
Figure 3. Invasive Therapies for ACS Patients in the COVID-19 Era. 
^ Acute MI with mechanical complications is best treated with surgical revascularization and concomitant repair 
(with adjunctive percutaneous ventricular assist devices).  ^^ Risk stratification after NSTE-ACS can be performed 
using an objective risk score (e.g. GRACE, TIMI).  * When pursuing an invasive approach, appropriate personal 
protective equipment (e.g. gowns, face shield/goggles, N95 masks) and set-up (e.g. negative pressure room) must be 
available for the safety of healthcare workers and patients. Otherwise, defaulting to the alternative approach 
(pharmacologic reperfusion or ischemia-guided strategy) after deliberation between the heart team members, 
invoking the ethics team when appropriate, and in a process of shared decision making with the patient and family.  
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** Fibrinolytic therapy should be administered within DTN of 30 minutes. Upon failure of pharmacologic 
reperfusion, rescue PCI is recommended.  *** Patients treated with an ischemia-guided strategy may cross over to 
an invasive strategy in case of significant spontaneous or inducible ischemia, or any evidence of hemodynamic or 
electrical instability.  **** Unsafe healthcare setting can be attributed to a myriad of factors (e.g. lack of PPE, lack 
of ventilators, shortage of healthcare workers, negative pressure cath lab not available).  LV (Left Ventricle), OMT 
(Optimal Medical Therapy), GRACE (Global Registry of Acute Coronary Events), PPE (Personal Protection 
Equipment), TIMI (Thrombolysis in Myocardial Infarction), OMT (Optimal Medical Therapy), DTN (Door-To-
Needle)  
 
ECMO in the COVID-19 Pandemic Era 
Take Home Points 
• Venovenous and venoarterial extracorporeal membrane oxygenation (ECMO) may be 
utilized as salvage therapies in COVID-19 patients with refractory respiratory or 
cardiorespiratory failure, respectively. 
• When needed, it is best to institute ECMO early before multiorgan failure ensues.  
• ECMO is a complex therapeutic modality that requires advanced expertise and intensive 
resource utilization. In the absence of definitive evidence supporting its utility, it should be used 
judiciously after careful assessment of the benefits and risks by a multifaceted medical team and 
with shared decision making with patient and family. 
 
The clinical presentation of patients with COVID-19 is variable.15 Hypoxemic respiratory failure 
requiring ICU admission occurs in 5-6% of patients, of whom the majority will require 
mechanical ventilation.91 The most common etiology for respiratory failure in these patients is 
acute respiratory distress syndrome (ARDS).18 Mortality rates are significantly high in patients 
who require mechanical ventilation and are reported to be 50%.18, 91 Furthermore, COVID-19 
patients on mechanical ventilation require prolonged duration of respiratory support with a 
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median of 17 days of ventilation.92 COVID-19 can also cause cardiovascular complications, 
including cardiac injury, myocarditis, heart failure, cardiogenic shock, tamponade, and 
pulmonary embolism.93–95 Patients with underlying cardiovascular disease (CVD) are more 
likely to suffer from myocardial injury with COVID-19, and this combination (underlying CVD 
and myocardial injury) portends the highest mortality (70%).6 
Venovenous (VV) and venoarterial (VA) extracorporeal membrane oxygenation (ECMO) 
can offer respiratory or cardiorespiratory support for patients with refractory respiratory or 
cardiorespiratory failure, respectively.96 ECMO is also used in cases of cardiac arrest in 
conjunction with cardiopulmonary resuscitation (E-CPR).97 Thus, ECMO could potentially offer 
a life-saving treatment to sick COVID-19 patients, as it did in prior Coronavirus epidemics.98 
ECMO is a complex therapeutic modality that requires intensive resource utilization and is 
usually offered in tertiary and quaternary centers with a full ECMO team. It is therefore 
important to understand its benefits and limitations, especially when resources are stretched and 
healthcare systems are overwhelmed as is the case in the current COVID-19 pandemic.96, 98    
There are conflicting reports regarding preliminary outcomes of ECMO use in sick 
COVID-19 patients. In one study, patients treated with ECMO had a mortality rate of 86%.4 In 
another study, 50% of patients treated with ECMO died, while 37.5% were successfully weaned 
off ECMO but remained on mechanical ventilation.99 A potential marker of poor prognosis in 
COVID-19 with ECMO is lymphopenia. Lymphopenia also occurred in prior Coronavirus 
epidemics and was caused by lymphocyte apoptosis.100 Lymphopenia occurs in 70% of 
symptomatic COVID-19 patients, and the degree of lymphopenia is associated with more severe 
disease and ICU admission.5, 12 ECMO use is associated with a decline in lymphocytic count and 
this potentially confounds the clinical course in COVID-19 patients.101 One possible explanation 
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of poor prognosis is the significant rise in cytokines and inflammatory biomarkers, although 
there are conflicting opinions on whether it is an association or implicated in the causal 
pathway.102 In COVID-19 patients, the cytokine release syndrome is associated with lower 
probability of survival.16 
Given the limited evidence for ECMO use in COVID-19 patients with ARDS, and the 
extensive resources and experience required to provide ECMO support, The Extracorporeal Life 
Support Organization (ELSO) released a guidance document.96 Several important issues should 
be taken into account when considering ECMO for COVID-19 patients (Table 5). First, it should 
be determined early which kind of support that patient would need, whether respiratory support 
only or whether there is evidence of myocardial dysfunction and cardiogenic shock requiring 
cardiorespiratory support. If ECMO is needed, it should be provided early in the course of 
mechanical ventilation, as prognosis is usually worse with longer duration on mechanical 
ventilation. Second, if ECMO is likely to be required, the consensus recommendation is to insert 
it early before multiorgan failure ensues. Third, ECMO may be futile in elderly patients with 
significant comorbidities in which survival is unlikely. This is important at a time when 
resources are limited and the healthcare system is strained, as is the case in the current COVID-
19 outbreak in several parts of the United States, Italy, and Spain. Fourth, a strong relationship 
between ECMO volume and outcome has been documented.103 It is highly advisable to refer 
COVID-19 patients who might require ECMO support to experienced centers, as the best 
survival outcomes were reported in centers performing at least 30 ECMO procedures annually.103 
Fifth, given the risk of significant aerosolization and disease transmission during 
cardiopulmonary resuscitation, and the number of personnel required in the room for E-CPR, it is 
probably ill-advised to utilize ECMO in COVID-19 patients with cardiac arrest. Finally, in 
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COVID-19 patients with severe left ventricular (LV) dysfunction (e.g. myocarditis, takotsubo 
cardiomyopathy) complicating their ARDS, increased LV wall stress and consequent myocardial 
ischemia from ECMO may exacerbate cardiac dysfunction. In these patients, venting the heart 
using an intra-aortic balloon pump (IABP) or a percutaneous ventricular assist device (e.g. 
Impella) may be a reasonable strategy, as it has been successfully utilized in cardiogenic shock 
patients. However, this should be only performed judiciously with consideration of available 
resources and expertise in the middle of a pandemic.  
It is probably too early in the pandemic to fully judge the utility of ECMO in the COVID-
19 era. Currently, it remains an indispensable therapeutic modality in the armamentarium of 
clinicians attempting to salvage a decompensated COVID-19 patient with ARDS. It is laudable 
that ELSO encouraged early entry of COVID-19 patients treated with ECMO into its registry by 
participating hospitals and waived membership fees during the pandemic.96 This will help the 
medical community examine the role of ECMO and inform clinical practice with critically-
needed evidence. 
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Table 5. Clinical and Procedural Considerations in COVD-19 Patients Undergoing 
Extracorporeal Membrane Oxygenation (ECMO) 
 
 
COVID-19 infection and the healthcare professional: mitigating the risk  
Take Home Points 
• Cardiovascular healthcare professionals are at risk of contracting COVID-19, and best 
practices should be implemented to reduce the risk of patient-provider and provider-provider 
exposure. 
Cannulation place Preferably bedside percutaneous cannulation using adequate Personal 
Protection Equipment (PPE) to avoid moving the patient to the OR with 
dislodgment of cannula and potential transmission of the infection. 
Resuscitation Avoid doing ECMO assisted CPR (E-CPR) given poor prognosis, limited PPE 
resources, and high potential for aerosol generation and infecting healthcare 
staff.  
Timing Attempt to implement ECMO placement as early as possible and before end-
organ damage occur. Also, avoid in patients with prolonged (usually > 7 days) 
of mechanical ventilation.  
Patient selection Consider avoiding in very elderly patients with significant burden of 
comorbidities due to futility.  
Shared decision making Patient- and family-centered discussions, early in the hospital course before 
clinical deterioration and continually, about goals of care, and extent of 
invasiveness desired by the patient.  
Center referral  May not be advisable for centers to start an ECMO program during the 
pandemic. Preferably, a centralized approach of referring COVID-19 cases for 
ECMO care early to high-volume experienced centers should be considered. 
Reporting Participation and reporting to ELSO network is encouraged, to generate 
evidence about the safety and effectiveness of ECMO in sick COVID-19 
patients. 
Capacity consideration Providing advanced ECMO care to critically ill COVID-19 patients should be 
balanced with the limitations of intensive care unit capacity in a pandemic. 
Blood borne transmission There is no evidence of possible blood transmission of COVID-19 yet. 
However, standard precautions with blood-borne pathogens should be always 
observed.    
Type of support Given reported cases of severe cardiac dysfunction and cardiogenic shock in 
some COVID-19 cases, early placement of VA ECMO or upgrade of VV 
ECMO to VA ECMO should be considered if end organ hypoperfusion 
becomes evident.  
Laboratory consideration Monitor blood counts, kidney and liver functions, electrolytes, D-dimers, 
cardiac and pro-inflammatory markers including interleukin-6 and ferritin. 
Standardized transfusion protocols should be used.    
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• Future research efforts should focus on reducing COVID-19 transmission, optimizing 
communication of risk, and understanding the long-term physical and psychosocial 
consequences of exposure. 
 
The protection of healthcare providers from COVID-19 exposure during this pandemic is of 
paramount importance. Cardiovascular physicians, nurses, technicians, and other healthcare 
professionals will be increasingly called upon to assist in the clinical care of patients with 
suspected or confirmed COVID-19, particularly those patients with underlying cardiovascular 
disease or those who develop cardiac complications. In order to best serve these patients, 
cardiovascular healthcare professionals must utilize best practices to protect their own physical 
health and emotional well-being. 
In China, 3.8% of patients infected with COVID-19 were healthcare workers while in 
Italy, healthcare workers accounted for 9% of total COVID-19 cases.66, 104 The clinical spectrum 
of COVID-19 infection ranges from asymptomatic infection to severe viral pneumonia with 
respiratory failure. Transmission risk occurs from both asymptomatic and symptomatic patients, 
with infection rates ranging from 1-5%.105 Cardiovascular healthcare professionals are at 
increased risk because COVID-19 is more prevalent in patients with cardiovascular 
comorbidities. The most common co-existing medical conditions in patients hospitalized with 
COVID-19 are hypertension (31%), cardiovascular disease (14%), and diabetes (10%).5 
Additionally, cardiovascular procedures place providers at increased risk due to the close contact 
needed with the patient and the potential for generation of respiratory droplets. 
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Precautions are needed at the societal, institutional, departmental, and administrator 
levels to protect cardiovascular healthcare professionals from COVID-19. Many societal 
professional meetings have been cancelled or converted to virtual platforms, including the 
American College of Cardiology 2020 Annual Scientific Session in Chicago, Illinois. Several 
healthcare institutions have also significantly restricted non-essential travel for faculty. To 
reduce COVID-19 exposure at the departmental level, the overall number of non-essential in-
person patient-provider encounters should be limited. Routine cardiology consultations and 
outpatient visits should be conducted virtually (e.g., telemedicine) whenever possible. Elective 
cardiology studies and procedures should be postponed to minimize exposure and preserve 
personal protective equipment (PPE) and resources. The performance of essential cardiology 
studies and procedures, particularly those involving suspected or confirmed COVID-19 patients, 
should be limited to essential personnel. At the administrator level, adequate supplies of PPE 
should be obtained and local COVID-related updates should be relayed in a timely and 
transparent manner to all healthcare workers. 
Precautions are also necessary at the personal level to protect cardiovascular healthcare 
professionals from COVID-19. Consideration should be given to limiting exposure of staff who 
may be particularly susceptible to the complications of COVID-19, including those with an age 
over 60 years, chronic medical conditions, and those who are immunocompromised or pregnant. 
While cardiovascular medical education remains important, restrictions should be placed on 
students and trainees who are not essential to direct clinical care to minimize exposure, and 
online platforms for learning (e.g., teleconferences) should be utilized when possible. 
When direct in-person patient care with COVID-19 patients is required, cardiovascular 
healthcare providers should strictly adhere to the latest Centers for Disease Control (CDC) 
D
ow
nloaded from
 http://ahajournals.org by on May 1, 2020
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved 
 
recommended guidelines.106 Current CDC guidelines indicate that COVID-19 is spread by both 
close contact (within 6 feet) and respiratory droplets (e.g., coughing or sneezing). Contact 
precautions include the use of a gown and gloves, and droplet precautions include the use of a 
facemask. To further minimize the risk of exposure when treating patients with suspected or 
confirmed COVID-19, the CDC recommends the use of eye protection (e.g., goggles or face-
shield) and a respirator (e.g., N95 or powered air purifying respiratory systems) instead of a 
facemask when possible, particularly for procedures that are likely to generate respiratory 
aerosols (e.g., trans-esophageal echocardiograms). Therefore, all cardiovascular staff should be 
fit-tested for N95 respirator masks and receive training on the proper use of PPE, including 
doffing and donning techniques, prior to participating in the direct clinical care of COVID-19 
patients. In contrast to the CDC guidelines, the World Health Organization (WHO) and Public 
Health England (PHE) currently recommend reserving respirators for aerosol-generating 
procedures.90, 107 
To reduce exposure risk during cardiac procedures, cardiac laboratories should be 
converted to a negative-pressure ventilation system whenever possible for optimal infection 
isolation and be thoroughly disinfected after procedures. To minimize the potential for 
cardiovascular staff shortages in the case of a procedural exposure, the separation of individuals 
with overlapping cardiovascular procedural skillsets should be considered. Specific procedural 
protocols for the management of acute cardiovascular conditions (e.g., acute myocardial 
infarction) should be developed for both patients with and without COVID-19. Due to the 
infectious risks in transporting hospitalized patients to cardiac laboratories, certain cardiac 
procedures (such as trans-esophageal echocardiogram and pulmonary artery catheter placement) 
should be considered to be performed at the bedside. For PPE recommendations regarding 
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specific cardiovascular aerosol-generating and non-aerosol-generating procedures, we 
recommend following sub-specialty guidelines.108–110 
In addition to appropriate patient-provider precautions, direct interactions with other 
healthcare providers should be conducted at a distance in accordance with social distancing. Staff 
rooms used by multiple healthcare providers should be frequently cleaned, with surface 
decontamination of commonly touched surfaces. Thorough and frequent handwashing is 
essential after visiting any public space, touching a common surface, touching of the face, and 
before and after eating. Cardiovascular providers should also clean personal items, such as 
stethoscopes and mobile phones, with hospital-provided disinfectants or alcohol-based 
disinfectants to prevent potential viral transmission. In accordance with social distancing, non-
essential travel and large gatherings of people should be avoided to minimize exposure risk.  
 It is also essential to recognize the psychological stress of COVID-19 exposure on 
cardiovascular healthcare providers. The pandemic has created newly unemployed spouses, 
difficulties finding childcare during school closures, loved ones at increased risk of disease, and 
a feeling of uncertainty. Among Chinese healthcare workers exposed to COVID-19, women, 
nurses, and frontline workers reported more severe symptoms of depression, anxiety, insomnia, 
and distress.111 Transparent and thoughtful communication from hospital leadership, local and 
state health departments, and the CDC is essential during this time. Interventions to promote 
psychosocial and emotional well-being should also be encouraged, including telemedicine 
therapy, mindfulness and meditation practices, and relaxation techniques.  
Despite the above measures to minimize COVID-19 exposure, the risk cannot be fully 
eliminated. Cardiovascular healthcare professionals must self-monitor, report signs of illness, 
and undergo self-quarantine or medical evaluation as needed. Antibody testing may help identify 
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cardiovascular healthcare workers exposed to COVID-19 infection who are safe to return to 
work and potentially immunized against future COVID-19 disease; although there is still an 
ongoing debate about how long, if at all, this immunity lasts for, and how good are these tests. 
As the medical community gains more experience with the COVID-19 pandemic, it will be 
essential to effectively communicate any updates in best practices to better protect cardiovascular 
healthcare professionals. When testing, vaccination, and treatments become (increasingly) 
available, the entire healthcare workforce should be considered a priority for evaluation and 
treatment. 
 
Ethical issues during the COVID-19 pandemic: triage, resource allocation, and patient 
rights 
Take Home Points 
• Internationally and in the US, serious ethical concerns have arisen as healthcare providers 
address triaging suspected COVID-19 patients; determining allocation of scarce resources; and 
honoring patients’ rights 
• Following recommendations based on ethical and process principles may help those 
infected, their families, their caregivers, and society cope with the growing tragedy of the 
COVID-19 pandemic 
Research Questions 
1. Are COVID-19 triage principles accurate in predicting which patients are most likely to 
survive? 
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2. Do vulnerable populations, as defined by Institutional Review Board criteria, have poorer 
outcomes following treatment for COVID-19 compared to non-vulnerable defined populations? 
 
The COVID-19 pandemic is unprecedented in the modern era. Numerous ethical 
concerns have arisen as internationally and, in the US, healthcare providers struggle to address 
grave issues: triaging suspected COVID-19 patients while preventing SARS-CoV-2 viral 
transmission to themselves, patients, and personnel; determining allocation of scarce resources; 
and honoring patients’ rights and preferences. Life-and-death decisions are required, in some 
cases, with no existing guidelines and no time to establish best practices; leading to the question: 
How can human and capital resources be fairly and equitably allocated during this pandemic?  
 Public health emergencies require healthcare grounded in ethical principles. Here we 
examine three ethical principles and present recommendations for practice during the COVID-19 
pandemic (See Table 6). Deontology is an ethical value proposing that an action should be based 
on whether it is right or wrong under a series of rules. This may include the assessment of 
preexisting conditions, risk stratification, prognosis, and protection of vulnerable groups.114 
Utilitarianism suggests that actions are right if they are useful or benefit the majority. This is 
represented by saving the most lives, provisioning required resources, evaluating quality of life 
years, and saving those viewed as the most valuable to society115 (e.g. giving priority care to first 
responders and healthcare workers). Egalitarianism is an ethical precept meaning that all people 
are equal and deserve equal opportunities. Examples include the equal right to care, principle of 
first come first served, access to clinical trials, or lottery systems.116 Understanding ethical 
principles can be useful to effectively develop processes to address crucial issues of triage, 
allocation of scare resources, and support of patients’ rights. 
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Triage  
 Arguably, one of the most dangerous jobs in a pandemic is that of triage personnel in the 
emergency department (ED). In normal times, the majority of individuals coming to the ED are 
undifferentiated and expose ED staff to unknown threats. In the pandemic milieu, both triage 
personnel and patients require adequate personal protective equipment (PPE) to remain free of 
disease or to prevent disease transmission. It is imperative that triage protocols with standardized 
triage acuity categories be applied fairly and equitably.115 Commonly used triage indices may 
need to be modified to protect staff and patients; however, the care of presumptive COVID-19 
patients should not supersede the treatment of other patients presenting to the ED with life-
threatening conditions such as acute myocardial infarction or stroke. 
Resource Allocation 
Of all the care that will be rationed, the most difficult will be the use of ventilators.117  
There are approximately 62,000 full function ventilators in the US,117 which is wholly 
insufficient if millions of Americans become infected as expected. The PPE is being rationed or 
reused at great risk to first responders, hospital staff, and the uninfected.116 Medications may also 
be rationed as hospitalizations increase. There are already reported shortages of 
hydroxychloroquine following unsubstantiated reports by government officials that it is an 
effective COVID-19 treatment. Deficiencies in available and reliable testing have also become a 
critical issue since infected carriers may be asymptomatic for weeks and go on to infect others3. 
Finally, without large-scaled testing, it is impossible to track true disease prevalence. Numerous 
authors have suggested frameworks for the allocation of scarce resources in the face of disasters 
such as a pandemic118, 119 with process principles to improve the likelihood of equitable care and 
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as a means to mitigate the moral distress experienced by frontline care providers. Recommended 
processes include a “triage officer,” central monitoring committee, and triage algorithm.120 
Patient Rights  
Maintaining patients’ rights to high quality care, autonomy, and privacy in the midst of a 
public health emergency is challenging.121 For example, the use of ventilators is not just a 
resource allocation issue. Who decides to initiate or terminate mechanical ventilation; the patient, 
family, or a committee? Crushing decisions as to who lives and dies based on individual and/or 
institutional criteria amid the surge are already taking place. Lack of transparency may also leave 
patients uninformed and suppress autonomy when their care is rationed due to scarce resources. 
Restricted visitation policies have caused great anguish for families by limiting or prohibiting 
presence at the bedside of their critically-ill loved ones. Clinical trials and access to 
investigational products present another ethical challenge when patients are not offered 
opportunities to participate or compassionate use (expanded access) studies have been 
discontinued in the patients’ most dire hour. Meanwhile, we may see critical drug shortages as 
increased demands disrupts pharmaceutical supply chains.  
The thought of rationing healthcare is anathema to the general public, and healthcare 
decisions are fraught with ethical and moral dilemmas that, by definition, may have no right or 
wrong answer. For triage, we recommend the use of a specific algorithm based on exclusion 
criteria and mortality risk; the use of a triage officer not involved in direct patient care, and fair 
and transparent decisions on care. For allocation of scarce resources, provide ventilators to those 
with greatest short and long-term chance for survival; provide PPE to all personnel caring for the 
infected, prescribe medications approved for a specific use, and distribute resources based on 
equal access. To preserve patients’ rights, limit visitation and provide for virtual visitation, 
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facilitate transparent discussion with patients and families on their right to receive or decline 
care, and convene a task force for expediting research. Following recommendations based on 
generally accepted ethical and process principles may help those infected, their families, their 
caregivers, and society as a whole cope with the growing tragedy of the COVID-19 pandemic 
and better prepare for the next pandemic.  
 
Table 6 
 
Ethical Concept Ethical Principle of 
Interest 
 
Recommendations for Application during COVID-19 
Pandemic 
Deontology- an 
action should be 
based on whether it is 
right or wrong under 
a series of rules (rule-
based or policy-
based) 
 Preexisting 
conditions 
 Risk stratification 
 Prognosis 
 Protecting vulnerable 
groups 
 
Triage 
 Develop triage algorithm based on exclusion 
criteria and assessment of mortality risk (e.g. SOFA 
score)4 and review regularly based on outcome 
measures and new knowledge of pandemic 
 Use of a triage officer/committee not involved in 
direct patient care to triage those presenting to the 
ED 
Allocation of Scarce Resources 
 Provide ventilators to those with greatest short and 
long-term chance for survival 
 Provide PPE to all personnel caring for the infected 
 Prescribe medication as approved for use, not for 
off label use 
Patients’ Rights 
 Create standards for emergency use of experimental 
treatments 
 Restrict visitation to reduce transmission of 
infection 
 Provide remote visitation via phone or tablet 
Utilitarianism- 
actions are right if 
they are useful or 
benefit the majority 
(balance or good vs. 
bad consequences) 
 Saving the most lives 
 Required resources 
 Quality of life years 
 Saving function of 
society 
 
Triage 
 Employ triage officer/committee not involved in 
direct patient care to decide priority for care 
Allocation of Scarce Resources 
 Direct critical resources to those who will benefit 
the most 
 Ventilators to those most likely to survive  
 Provide intensive care and medications for those 
most likely to survive 
Patients’ Rights 
 Transparent discussion with patients and families 
about their right to decline care or request care 
Egalitarianism- all 
people are equal and 
 Equal rights 
 Unbiased selection 
Triage 
 Include vulnerable populations 
 Make decisions based on fairness and transparency  
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deserve equal 
opportunities 
 Research 
 First come, first 
served 
 Lottery 
 Triage to appropriate level of care and resources 
Allocation of Scarce Resources 
 Distribute resources based on equal access (non-
discrimination) 
 Provide equal opportunity for all patients to 
experience the stages of life from childhood to old 
age, and prioritize resources according to this life-
cycle principle112 
Patients’ Rights 
 Develop Task Forces for expediting all forms of 
research, assuring access to data, informed consent, 
expedient IRB reviews, and inclusion of all 
populations113 
 Compassionate use of PPE by family members for 
patients at the end of life,112 if possible, or provide 
videoconferencing technology to connect patients 
and families. 
 
CONCLUSIONS 
The novel coronavirus pandemic is a unique event during our lifetimes. Prior pandemics 
including HIV and H1N1 influenza had cardiac sequelae but differed significantly: HIV was 
initially highly lethal but less contagious than COVID-19, while H1N1 was highly contagious 
but had lower lethality than COVID-19. For both HIV and H1N1, however, the cardiac effects 
were less clearly apparent early during the course of the pandemic.  
The ramifications of the COVID-19 pandemic are tragic, when considering the millions of 
infected patients, the strain on the healthcare system and the effects on the world’s economy. 
This Perspective Article and many others like it highlight how little we currently understand 
about COVID-19 and its cardiac effects. The intense study of the virus and its effects on the 
heart should correct this deficit. Both the National Institutes of Health and the American Heart 
Association have solicited grants to study cardiac effects of the virus. JAHA has already received 
dozens of manuscripts related to COVID-19. It is likely that we will soon understand much more 
regarding the effects of the virus on the heart and the role of cardiovascular disease in 
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modulating viral infection. In addition, these studies will likely teach us something fundamental 
about cardiovascular physiology and pathophysiology that transcend the current  pandemic. 
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